Earnings Estimates Moving Higher for Dentsply (XRAY): Time to Buy?

Dentsply International (XRAY) is exhibiting positive momentum, with a 17.2% gain in the past four weeks, driven by rising earnings estimates; the consensus EPS estimate for the current quarter has increased by 9.41% to $0.50, a 2.04% year-over-year increase, and the full-year estimate is up 5.06% to $1.89, a 13.17% increase from the prior year. This positive revision trend has earned Dentsply a Zacks Rank #2 (Buy), suggesting potential outperformance.

Analysis

Dentsply Sirona Inc. (XRAY) is exhibiting significant positive momentum, underscored by a 17.2% increase in its share price over the past four weeks. This appreciation appears directly linked to improving earnings estimates, reflecting growing analyst optimism regarding the dental products manufacturer's financial prospects. For the current quarter, Dentsply is projected to earn $0.50 per share, a 2.04% year-over-year increase; the Zacks Consensus Estimate for this period has risen by 9.41% in the last 30 days, supported by eight upward revisions and no negative revisions from analysts. Looking at the full year, the company is expected to achieve an EPS of $1.89, marking a 13.17% increase from the prior year. This annual consensus estimate has also seen a positive adjustment, increasing by 5.06% over the past month due to nine upward estimate revisions and no downward changes. These favorable estimate revisions have contributed to Dentsply earning a Zacks Rank #2 (Buy), a rating system which, according to the article, has a strong track record, with Zacks #1 and #2 ranked stocks historically outperforming the S&P 500. The core of this positive outlook is the empirically observed strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Key Decisions for Investors

• Given the strong upward trend in earnings estimate revisions and recent share price appreciation of 17.2%, investors may consider Dentsply International for inclusion in portfolios targeting growth, particularly as it holds a Zacks Rank #2 (Buy).
• Investors should continue to monitor analyst earnings estimate revisions for Dentsply, as these are highlighted as a key driver of near-term stock performance according to the underlying research methodology.
• The current consensus EPS estimates, $0.50 for the current quarter (+2.04% YoY) and $1.89 for the full year (+13.17% YoY), suggest a positive earnings trajectory that could support further stock price gains if met or exceeded.